ApcinteX Raises £14m in Series A Funding

ApcinteX Limited, a University of Cambridge (UK) spin-out company developing a new therapy for haemophilia, raised £14m in Series A funding.

The round was co-led by Medicxi and Touchstone Innovations Group plc (AIM: IVO), with participation from Cambridge Enterprise, which helped in ApcinteX’s formation, licensing key intellectual property to the company.

Based on the work of Professor Jim Huntington (Cambridge Institute for Medical Research) and Dr Trevor Baglin (Cambridge University Hospitals), Apcintex has developed a new treatment that seeks to turn down the activity of a key natural anticoagulant pathway to produce normal blood clotting in patients with haemophilia. This means that the drug could potentially treat patients with all types of haemophilia, including those who develop antibodies to replacement factors.



Join the discussion